Skip to main content

Table 2 Response assessment.

From: Combination therapy with docetaxel and S-1 as a first-line treatment in patients with advanced or recurrent gastric cancer: a retrospective analysis

  No. of patients %
Complete response 0 0
Partial response 44 52.4
Stable disease 37 44.0
Progressive disease 3 3.6
  1. The overall response rate was 52.4% (95% confidence interval, 42.9-64.5)